Year: 2013

Teva questions safety of MS drug from rival Biogen

Your Health Matters

(Reuters) – Teva Pharmaceutical Industries Ltd, which makes the market-leading multiple sclerosis drug Copaxone, has filed a petition with the U.S. Food and Drug Administration that could, if granted, delay entry to the market of a rival drug developed by Biogen Idec Inc. Teva’s petition asks that the FDA not approve any new multiple sclerosis drug until its safety has been evaluated by a panel of outside advisors, and said it had uncovered “troubling information” on a publicly accessible website about the safety of Biogen’s drug, BG-12. …

, , ,

Poor people participate in cancer trials less often

Your Health Matters

NEW YORK (Reuters Health) – Poor people are less likely to take part in clinical trials for new cancer drugs, which can make it harder to develop treatments, according to a new study. “Cancer clinical trials are how we move the field forward. As a result of patients not participating in clinical trials, it takes a lot longer and it’s much more expensive to develop new therapies,” said Dr. Dawn Hershman, who worked on the study. “In this study we found one factor that contributes to that is patient income,” Hershman, from Columbia University in New York, told Reuters Health. …

, , ,

One in 25 youth attempt suicide: U.S. study

Your Health Matters

NEW YORK (Reuters Health) – About one in 25 U.S. teens has attempted suicide, according to a new national study, and one in eight has thought about it. Researchers said those numbers are similar to the prevalence of lifetime suicidal thinking and attempts reported by adults – suggesting the teenage years are an especially vulnerable time. “What adults say is, the highest risk time for first starting to think about suicide is in adolescence,” said Matthew Nock, a psychologist who worked on the study at Harvard University in Cambridge, Massachusetts. …

,
1 … 949 950 951 952 953 … 977